Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) has received mixed analyst ratings over the past three months, with an updated average 12-month price target of $13.00, reflecting a 4.0% increase from the previous target. The company, focusing on rare kidney, liver, and metabolic diseases, has shown a revenue growth of 53.58% as of December 31, 2023, but trails behind industry peers in the Health Care sector. Despite a high net margin of -200.12%, its ROE and ROA are below industry averages, and its debt-to-equity ratio of 2.02 indicates a higher financial risk.
April 17, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Travere Therapeutics has received mixed analyst ratings, with a revised average 12-month price target of $13.00. The company's financial performance shows significant revenue growth but is challenged by below-average ROE, ROA, and a high debt-to-equity ratio.
The mixed analyst ratings and the revised price target suggest a cautious optimism towards Travere Therapeutics. The significant revenue growth indicates potential, but the financial challenges highlighted by the below-average ROE, ROA, and high debt-to-equity ratio could dampen short-term stock performance. The overall impact is neutral due to these balancing factors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100